US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
US5169939A
(en)
|
1985-05-21 |
1992-12-08 |
Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College |
Chimeric antibodies
|
US4720449A
(en)
|
1985-06-03 |
1988-01-19 |
Polaroid Corporation |
Thermal imaging method
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
WO1991000906A1
(en)
|
1989-07-12 |
1991-01-24 |
Genetics Institute, Inc. |
Chimeric and transgenic animals capable of producing human antibodies
|
US6713610B1
(en)
|
1990-01-12 |
2004-03-30 |
Raju Kucherlapati |
Human antibodies derived from immunized xenomice
|
JP3068180B2
(en)
|
1990-01-12 |
2000-07-24 |
アブジェニックス インコーポレイテッド |
Generation of heterologous antibodies
|
US6657103B1
(en)
|
1990-01-12 |
2003-12-02 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US7041871B1
(en)
|
1995-10-10 |
2006-05-09 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US7084260B1
(en)
|
1996-10-10 |
2006-08-01 |
Genpharm International, Inc. |
High affinity human antibodies and human antibodies against human antigens
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
ATE158021T1
(en)
|
1990-08-29 |
1997-09-15 |
Genpharm Int |
PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
WO1993004169A1
(en)
|
1991-08-20 |
1993-03-04 |
Genpharm International, Inc. |
Gene targeting in animal cells using isogenic dna constructs
|
CA2124967C
(en)
|
1991-12-17 |
2008-04-08 |
Nils Lonberg |
Transgenic non-human animals capable of producing heterologous antibodies
|
ES2301158T3
(en)
|
1992-07-24 |
2008-06-16 |
Amgen Fremont Inc. |
XENOGENIC ANTIBODY PRODUCTION.
|
DE4228162C1
(en)
|
1992-08-25 |
1994-01-13 |
Rajewsky Klaus Dr |
Method for replacing homologous gene segments from mammals in the germline of non-human mammals
|
JP4242447B2
(en)
|
1993-01-22 |
2009-03-25 |
イミュネックス・コーポレーション |
Detection and treatment of CD40 ligand gene mutations
|
AU6819494A
(en)
|
1993-04-26 |
1994-11-21 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
DE4331162A1
(en)
|
1993-09-14 |
1995-03-16 |
Bayer Ag |
Process for the preparation of cyanine dyes
|
US7119248B1
(en)
|
1994-04-12 |
2006-10-10 |
Miltenyi Biotec Gmbh |
Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
|
US6130364A
(en)
|
1995-03-29 |
2000-10-10 |
Abgenix, Inc. |
Production of antibodies using Cre-mediated site-specific recombination
|
AU3507297A
(en)
|
1996-06-26 |
1998-01-14 |
Baylor College Of Medicine |
Chromosomal rearrangement by insertion of two recombination substrates
|
DK0937140T3
(en)
|
1996-06-27 |
2008-01-28 |
Vlaams Interuniv Inst Biotech |
Antibody molecules that interact specifically with the active site or cleavage of a target molecule
|
KR20080059467A
(en)
|
1996-12-03 |
2008-06-27 |
아브게닉스, 인크. |
Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
|
US6319906B1
(en)
|
1996-12-31 |
2001-11-20 |
Isis Pharmaceuticals |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
JP4213224B2
(en)
|
1997-05-02 |
2009-01-21 |
ジェネンテック,インコーポレーテッド |
Method for producing multispecific antibody having heteromultimer and common component
|
US20020088019A1
(en)
|
1997-09-02 |
2002-07-04 |
Oron Yacoby-Zeevi |
Methods of and pharmaceutical compositions for improving implantation of embryos
|
PT1034262E
(en)
|
1997-11-18 |
2005-10-31 |
Pioneer Hi Bred Int |
COMPOSITIONS AND METHODS FOR THE GENETIC MODIFICATION OF PLANTS
|
EP0939120A1
(en)
|
1998-02-27 |
1999-09-01 |
Gesellschaft für biotechnologische Forschung mbH (GBF) |
Method for marker-free repetitive DNA expression cassette exchange in the genome of cells or parts of cells
|
GB9823930D0
(en)
|
1998-11-03 |
1998-12-30 |
Babraham Inst |
Murine expression of human ig\ locus
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
AU5867100A
(en)
|
1999-05-03 |
2000-12-12 |
Medarex, Inc. |
Human antibodies to staphylococcus aureus
|
US6833268B1
(en)
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
CA2307503A1
(en)
|
2000-05-02 |
2001-11-02 |
Carlos F. Barbas Iii |
Peptides for use as a vaccine or treatment for hiv infection
|
EP1309709A2
(en)
|
2000-07-21 |
2003-05-14 |
The United States of America, represented by The Secretary of Agriculture |
Methods for the replacement, translocation and stacking of dna in eukaryotic genomes
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US6586251B2
(en)
|
2000-10-31 |
2003-07-01 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US7105348B2
(en)
|
2000-10-31 |
2006-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
DE60144305D1
(en)
|
2000-11-17 |
2011-05-05 |
Kyowa Hakko Kirin Co Ltd |
Expression of xenogeneic (human) immunoglobulins in cloned, transgenic ungulates
|
US7041870B2
(en)
|
2000-11-30 |
2006-05-09 |
Medarex, Inc. |
Transgenic transchromosomal rodents for making human antibodies
|
AU2002246733B2
(en)
|
2000-12-19 |
2007-09-20 |
Altor Bioscience Corporation |
Transgenic animals comprising a humanized immune system
|
ME00502B
(en)
|
2001-01-05 |
2011-10-10 |
Amgen Fremont Inc |
Antibodies to insulin-like growth factor i receptor
|
JP2003000243A
(en)
|
2001-06-25 |
2003-01-07 |
Takachika Azuma |
Method for producing mutant
|
FR2827302B1
(en)
|
2001-07-13 |
2003-10-10 |
Genoway |
TRANSGENIC CELL AND ANIMAL MODELING HUMAN ANTIGENIC PRESENTATION AND USES THEREOF
|
US20060199204A1
(en)
|
2001-10-05 |
2006-09-07 |
U.S. Epa |
Genetic testing for male factor infertility
|
US20030108925A1
(en)
|
2001-10-05 |
2003-06-12 |
U.S. Epa |
Genetic testing for male factor infertility
|
CA2847885C
(en)
*
|
2001-11-30 |
2022-03-22 |
Amgen Fremont Inc. |
Transgenic animals bearing human ig.lambda. light chain genes
|
US20050095712A1
(en)
|
2002-01-17 |
2005-05-05 |
Alberto Martin |
Mutations caused by activation-induced cytidine deaminase
|
US8877901B2
(en)
|
2002-12-13 |
2014-11-04 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
SI1523496T1
(en)
|
2002-07-18 |
2011-11-30 |
Merus B V |
Recombinant production of mixtures of antibodies
|
JP2005537805A
(en)
|
2002-09-09 |
2005-12-15 |
カリフォルニア インスティチュート オブ テクノロジー |
Methods and compositions for making humanized mice
|
DE10251918A1
(en)
|
2002-11-08 |
2004-05-19 |
Horn, Carsten, Dipl.-Biochem. Dr. |
Inheritable integration of DNA into germ-line invertebrate cells, useful for large-scale production of transgenic insects, includes post-transformational removal of mobilizable elements to increase stability
|
US7700356B2
(en)
|
2002-11-08 |
2010-04-20 |
The United States Of America As Represented By The Secretary Of Agriculture |
System for gene targeting and producing stable genomic transgene insertions
|
AR042145A1
(en)
|
2002-11-27 |
2005-06-08 |
Dow Agrociences Llc |
IMMUNOGLOBULIN PRODUCTION IN PLANTS WITH A REDUCED FUCOCILATION
|
GB2398784B
(en)
|
2003-02-26 |
2005-07-27 |
Babraham Inst |
Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
WO2004106375A1
(en)
|
2003-05-30 |
2004-12-09 |
Merus Biopharmaceuticals B.V. I.O. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
US7205148B2
(en)
|
2003-06-11 |
2007-04-17 |
Regeneron Pharmaceuticals, Inc. |
Genome mutation by intron insertion into an embryonic stem cell genome
|
GB2403475B
(en)
|
2003-07-01 |
2008-02-06 |
Oxitec Ltd |
Stable integrands
|
US7663017B2
(en)
|
2003-07-30 |
2010-02-16 |
Institut Pasteur |
Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
|
US20050153392A1
(en)
|
2003-08-11 |
2005-07-14 |
Roland Buelow |
Transgenesis with humanized immunoglobulin loci
|
US7604994B2
(en)
|
2003-09-03 |
2009-10-20 |
Morphotek, Inc. |
Genetically altered antibody-producing cell lines with improved antibody characteristics
|
CA2445602C
(en)
|
2003-10-20 |
2014-01-14 |
Campusgen Gmbh |
Nucleotide sequence for creatinine deiminase and method of use
|
CN102838675B
(en)
|
2003-12-10 |
2014-07-30 |
梅达雷克斯有限责任公司 |
Ip-10 antibodies and their uses
|
AU2005227313A1
(en)
|
2004-03-19 |
2005-10-06 |
Amgen Inc. |
Reducing the risk of human and anti-human antibodies through V gene manipulation
|
US7625549B2
(en)
|
2004-03-19 |
2009-12-01 |
Amgen Fremont Inc. |
Determining the risk of human anti-human antibodies in transgenic mice
|
EP2311874B1
(en)
|
2004-07-22 |
2017-05-31 |
Erasmus University Medical Center Rotterdam |
Binding molecules
|
FR2875239B1
(en)
|
2004-09-10 |
2007-07-20 |
Inst Necker Ass Loi De 1901 |
METHOD FOR THE ACCELERATION OF SOMATIC MUTATIONS AND ITS APPLICATION IN PROTEOMICS
|
WO2006029459A1
(en)
|
2004-09-13 |
2006-03-23 |
Evogenix, Inc |
Antibodies specific for hepatocellular carcinoma and other carcinomas and uses thereof
|
WO2006044492A2
(en)
|
2004-10-14 |
2006-04-27 |
Ingenious Targeting Laboratory, Inc. |
Methods for generating rat embryo-derived cell lines and genetic modification of rat genome
|
AU2005295269B2
(en)
|
2004-10-19 |
2010-05-13 |
Regeneron Pharmaceuticals, Inc. |
Method for generating an animal homozygous for a genetic modification
|
WO2006055704A2
(en)
|
2004-11-17 |
2006-05-26 |
Curagen Corporation |
Antibodies directed to ten-m proteins and uses thereof
|
AU2005319382B2
(en)
|
2004-12-21 |
2011-04-07 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
US20080196112A1
(en)
|
2005-04-29 |
2008-08-14 |
Innate Pharma, S.A. |
Transgenic Animals and Methods of Making Recombinant Antibodies
|
MX2007014139A
(en)
|
2005-05-14 |
2008-10-09 |
Univ Fudan |
Piggybac as a tool for genetic manipulation and analysis in vertebrates.
|
EP1780272A1
(en)
|
2005-10-27 |
2007-05-02 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Method for enhancing somatic hypermutation, gene conversion and class switch recombination
|
GB0601513D0
(en)
|
2006-01-25 |
2006-03-08 |
Univ Erasmus Medical Ct |
Binding molecules 3
|
AU2007219159B8
(en)
|
2006-01-25 |
2012-06-28 |
Roger Kingdon Craig |
Generation of heavy-chain only antibodies in transgenic animals
|
US7462759B2
(en)
|
2006-02-03 |
2008-12-09 |
Pioneer Hi-Bred International, Inc. |
Brittle stalk 2 gene family and related methods and uses
|
EP2003960B1
(en)
|
2006-03-31 |
2015-06-10 |
E. R. Squibb & Sons, L.L.C. |
Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
|
ATE537190T1
(en)
|
2006-06-02 |
2011-12-15 |
Regeneron Pharma |
HIGH AFFINE ANTIBODIES AGAINST THE HUMAN IL-6 RECEPTOR
|
AU2007345747A1
(en)
|
2006-06-27 |
2008-08-07 |
Vaxdesign Corporation |
Models for vaccine assessment
|
EP1878342A1
(en)
|
2006-07-13 |
2008-01-16 |
Institut Pasteur |
Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
|
EP2061812A4
(en)
|
2006-08-22 |
2010-06-09 |
G2 Inflammation Pty Ltd |
Method for producing antibodies
|
RU2445318C2
(en)
|
2006-10-02 |
2012-03-20 |
Ридженерон Фармасьютикалз, Инк. |
High-affinity human il-4 receptor antibodies
|
US7732195B2
(en)
|
2006-11-01 |
2010-06-08 |
Facet Biotech Corporation |
Tethered vectors for cell surface immunoglobulin display
|
NO347649B1
(en)
|
2006-12-14 |
2024-02-12 |
Regeneron Pharma |
Human antibody or antibody fragment that specifically binds human delta-like ligand 4 (hDII4), nucleic acid molecule that codes for such and vector and host-vector systems, as well as method for production, composition and use.
|
GB0700194D0
(en)
|
2007-01-05 |
2007-02-14 |
Univ Edinburgh |
Humanisation of animals
|
WO2008103474A1
(en)
|
2007-02-20 |
2008-08-28 |
Anaptysbio, Inc. |
Methods of generating libraries and uses thereof
|
CN101679512A
(en)
|
2007-02-21 |
2010-03-24 |
马萨诸塞州大学 |
Anti-hepatitis c virus (HCV) people antibody and uses thereof
|
CA2680237C
(en)
|
2007-03-27 |
2018-11-06 |
Sea Lane Biotechnologies, Llc |
Constructs and libraries comprising antibody surrogate light chain sequences
|
GB0706628D0
(en)
|
2007-04-04 |
2007-05-16 |
Univ Erasmus |
Germ-line manipulation 1
|
DK2336329T3
(en)
|
2007-06-01 |
2013-01-07 |
Omt Inc |
COMPOSITIONS AND PROCEDURES FOR INHIBITING ENDOGENIC IMMUNGLOBULATIONS AND FOR PRODUCING TRANSGENE, HUMAN, IDIOTYPIC ANTIBODIES
|
WO2009013620A2
(en)
|
2007-06-11 |
2009-01-29 |
Erasmus University Medical Center Rotterdam |
Homologous recombination
|
PL2178916T3
(en)
|
2007-07-31 |
2015-08-31 |
Regeneron Pharma |
Human antibodies to human cd20 and method of using thereof
|
US9693539B2
(en)
|
2007-08-10 |
2017-07-04 |
E. R. Squibb & Sons, L.L.C. |
HCO32 and HCO27 and related examples
|
CA2695997C
(en)
|
2007-08-10 |
2016-11-22 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human nerve growth factor
|
PL2592148T3
(en)
|
2007-10-12 |
2019-01-31 |
F. Hoffmann-La Roche Ag |
Protein expression from multiple nucleic acids
|
NZ586149A
(en)
|
2007-12-10 |
2012-05-25 |
Ablexis Llc |
Methods for sequential replacement of targeted region by homologous recombination
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
US20110107445A1
(en)
|
2008-03-26 |
2011-05-05 |
Iti Scotland Limited |
Efficient Insertion of DNA Into Embryonic Stem Cells
|
CA2721231C
(en)
|
2008-04-14 |
2015-10-06 |
Innovative Targeting Solutions Inc. |
Sequence diversity generation in immunoglobulins
|
US20110123527A1
(en)
|
2008-05-23 |
2011-05-26 |
Hiroaki Shizuya |
Method of generating single vl domain antibodies in transgenic animals
|
MX2010014542A
(en)
|
2008-06-27 |
2011-04-05 |
Merus B V |
Antibody producing non-human mammals.
|
KR101826224B1
(en)
|
2008-09-30 |
2018-02-06 |
아블렉시스, 엘엘씨 |
Non-human mammals for the production of chimeric antibodies
|
JO3672B1
(en)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
High Affinity Human Antibodies to PCSK9
|
CA2747534C
(en)
|
2008-12-18 |
2020-08-18 |
Erasmus University Medical Center Rotterdam |
Non-human transgenic animals expressing humanised antibodies and use therof
|
US9085795B2
(en)
|
2009-02-04 |
2015-07-21 |
Molecular Innovations, Inc. |
Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin and antibodies
|
US20110305692A1
(en)
|
2009-02-24 |
2011-12-15 |
Glaxo Group Limited |
Antigen-binding contructs
|
GB0905023D0
(en)
|
2009-03-24 |
2009-05-06 |
Univ Erasmus Medical Ct |
Binding molecules
|
AU2010230985B2
(en)
|
2009-04-03 |
2015-09-24 |
United Kingdom Research And Innovation |
Mutants of activation-induced cytidine deaminase (AID) and methods of use
|
TWI560271B
(en)
|
2009-06-26 |
2016-12-01 |
Sealane Biotechnologies Llc |
Expression of surrogate light chains
|
DK2564695T3
(en)
|
2009-07-08 |
2015-05-26 |
Kymab Ltd |
Animal models and therapeutic molecules
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
US20120204278A1
(en)
|
2009-07-08 |
2012-08-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
CA2768207C
(en)
|
2009-07-15 |
2019-12-03 |
Aimm Therapeutics B.V. |
Means and methods for producing high affinity antibodies
|
JO3182B1
(en)
|
2009-07-29 |
2018-03-08 |
Regeneron Pharma |
High Affinity Human Antibodies to Human Angiopoietin-2
|
WO2011019844A1
(en)
|
2009-08-13 |
2011-02-17 |
Crystal Bioscience Inc. |
Transgenic animal for production of antibodies having minimal cdrs
|
JP2013508287A
(en)
*
|
2009-10-14 |
2013-03-07 |
ヤンセン バイオテツク,インコーポレーテツド |
Methods for affinity maturation of antibodies
|
JP2013509878A
(en)
|
2009-11-05 |
2013-03-21 |
アナプティスバイオ インコーポレイティッド |
Method for producing improved antigen-binding agent using chain shuffling and optionally somatic hypermutation
|
CA2781159A1
(en)
|
2009-11-17 |
2011-05-26 |
Kyowa Hakko Kirin Co., Ltd. |
Human artificial chromosome vector
|
WO2011071957A1
(en)
|
2009-12-07 |
2011-06-16 |
Sea Lane Biotechnologies, Llc |
Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
|
MY172472A
(en)
|
2009-12-10 |
2019-11-26 |
Regeneron Pharma |
Mice that make heavy chain antibodies
|
WO2011097603A1
(en)
|
2010-02-08 |
2011-08-11 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
CN103025344B
(en)
|
2010-05-17 |
2016-06-29 |
桑格摩生物科学股份有限公司 |
Novel DNA-associated proteins and application thereof
|
AU2011266843C9
(en)
*
|
2010-06-17 |
2018-03-01 |
Kymab Limited |
Animal models and therapeutic molecules
|
CN104404050B
(en)
|
2010-06-22 |
2018-06-08 |
瑞泽恩制药公司 |
hybrid light chain mice
|
CN103282560B
(en)
*
|
2010-07-16 |
2016-08-03 |
阿迪马布有限责任公司 |
Antibody library
|
SG10201912639SA
(en)
|
2010-08-02 |
2020-02-27 |
Regeneron Pharma |
Mice that make binding proteins comprising vl domains
|
CA2808482C
(en)
|
2010-08-16 |
2021-10-26 |
Novimmune S.A. |
Methods for the generation of multispecific and multivalent antibodies
|
JO3375B1
(en)
|
2010-11-08 |
2019-03-13 |
Regeneron Pharma |
Human antibodies to human tnf-like ligand 1a (tl1a)
|
KR20130118925A
(en)
|
2010-12-22 |
2013-10-30 |
제넨테크, 인크. |
Anti-pcsk9 antibodies and methods of use
|
ME02106B
(en)
|
2011-02-25 |
2015-10-20 |
Regeneron Pharma |
Adam6 mice
|
IL273982B2
(en)
|
2011-08-05 |
2023-03-01 |
Regeneron Pharma |
Humanized universal light chain mice
|
CN107056936B
(en)
*
|
2011-09-19 |
2021-09-03 |
科马布有限公司 |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
WO2013041845A2
(en)
*
|
2011-09-19 |
2013-03-28 |
Kymab Limited |
Animals, repertoires & methods
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
PT3216871T
(en)
|
2011-10-17 |
2022-03-15 |
Regeneron Pharma |
Restricted immunoglobulin heavy chain mice
|
US20130102031A1
(en)
|
2011-10-25 |
2013-04-25 |
Anaptysbio, Inc. |
Use of somatic hypermutation to create insertion and deletion mutations in vitro
|
GB2496375A
(en)
|
2011-10-28 |
2013-05-15 |
Kymab Ltd |
A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
GB201122047D0
(en)
|
2011-12-21 |
2012-02-01 |
Kymab Ltd |
Transgenic animals
|
US20180295821A1
(en)
|
2011-12-02 |
2018-10-18 |
Kymab Limited |
Transgenic Animals
|
SG10201913164YA
(en)
|
2011-12-20 |
2020-03-30 |
Regeneron Pharma |
Humanized light chain mice
|
NZ627977A
(en)
|
2012-02-01 |
2016-06-24 |
Regeneron Pharma |
Humanized rodents that express heavy chains containing vl domains
|
BR112014021251A2
(en)
|
2012-03-02 |
2017-06-27 |
Regeneron Pharma |
human antibodies to clostridium difficile toxins
|
RU2683514C2
(en)
*
|
2012-03-06 |
2019-03-28 |
Регенерон Фармасьютикалз, Инк. |
Common light chain mouse
|
RU2014141536A
(en)
|
2012-03-16 |
2016-05-10 |
Регенерон Фармасьютикалз, Инк. |
MICE WHICH PRODUCE ANTIGEN-BINDING PROTEINS WITH PH-DEPENDENT BINDING CHARACTERISTICS
|
WO2013144567A1
(en)
|
2012-03-28 |
2013-10-03 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
JO3820B1
(en)
|
2012-05-03 |
2021-01-31 |
Regeneron Pharma |
Human antibodies to fel d1 and methods of use thereof
|
JP6343605B2
(en)
|
2012-05-25 |
2018-06-13 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Methods and compositions for RNA-dependent target DNA modification and RNA-dependent transcriptional regulation
|
CA2876172C
(en)
|
2012-06-12 |
2021-01-19 |
Regeneron Pharmaceuticals, Inc. |
Humanized non-human animals with restricted immunoglobulin heavy chain loci
|
US8962913B2
(en)
|
2012-06-18 |
2015-02-24 |
Regeneron Pharmaceuticals, Inc. |
Humanized IL-7 rodents
|
AU2013359199C1
(en)
|
2012-12-12 |
2021-06-17 |
Massachusetts Institute Of Technology |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
JP5993102B2
(en)
|
2013-02-20 |
2016-09-14 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
Non-human animals having modified immunoglobulin heavy chain sequences
|
US10993420B2
(en)
|
2013-03-15 |
2021-05-04 |
Erasmus University Medical Center |
Production of heavy chain only antibodies in transgenic mammals
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
US20150033372A1
(en)
|
2013-05-01 |
2015-01-29 |
Kymab Limited |
Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
US20140331339A1
(en)
|
2013-05-03 |
2014-11-06 |
Kymab Limited |
Transgenic Non-Human Assay Vertebrates, Assays and Kits
|
US20140331344A1
(en)
|
2013-05-03 |
2014-11-06 |
Kymab Ltd. |
Transgenic Animals
|
EP3051942B1
(en)
|
2013-10-01 |
2020-09-02 |
Kymab Limited |
Animal models and therapeutic molecules
|
GB201710984D0
(en)
|
2017-07-07 |
2017-08-23 |
Kymab Ltd |
Cells, vertebrates, populations & methods
|